Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

15.22
+0.47003.19%
Post-market: 15.05-0.1700-1.12%19:54 EDT
Volume:3.88M
Turnover:58.72M
Market Cap:1.50B
PE:-2.61
High:15.28
Open:14.90
Low:14.67
Close:14.75
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.82
T/O Rate:4.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-5.14
PE(LYR):-2.61

Loading ...

Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving up Yet.

Dow Jones
·
Sep 03

U.S. Stocks on the MOVE-Snowflake, Ultragenyx Pharmaceutical, Broadcom

Reuters
·
Sep 03

Top Premarket Decliners

MT Newswires Live
·
Sep 03

Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $23 From $30, Maintains Neutral Rating

MT Newswires Live
·
Sep 03

Canaccord Genuity Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 03

Ultragenyx price target lowered to $37 from $83 at Canaccord

TIPRANKS
·
Sep 03

Ultragenyx price target lowered to $25 from $50 at H.C. Wainwright

TIPRANKS
·
Sep 03

Stocks to Watch: Snowflake, Broadcom, HPE, Ultragenyx

Dow Jones
·
Sep 03

Ultragenyx Pharma is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 03

Ultragenyx Pharmaceutical Shares Crash 45% After Angelman Syndrome Drug Trial Disappoints

Trading Random
·
Sep 03

Ultragenyx Pharmaceutical Inc. : Baird Cuts to Neutral Rating; Cuts Target Price to $16 from $40

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical Inc. : TD Cowen Cuts Target Price to $18 from $49

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical Inc. : Canaccord Genuity Cuts Target Price to $37 from $83

THOMSON REUTERS
·
Sep 03

Ultragenyx downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Sep 03

Evercore ISI downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
Sep 03

William Blair downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours

MT Newswires Live
·
Sep 03

Ultragenyx Pharmaceutical to Cut Costs After Drug Trial Misses Endpoints

Dow Jones
·
Sep 03

Ultragenyx's Rare Disease Drug Fails in Late-Stage Trial

Reuters
·
Sep 03